Replies to post #213785 on Biotech Values

[DewDiligence]

ENTA—Apparently, the observed safety metrics enabled higher dosing than in the original plan. They added one dose in the SAD portion of the trial (in healthy volunteers) and three doses in the MAD portion of the trial (in presumed NAFLD patients).